Tag Archives: SRPT

A Director at Sarepta Therapeutics (NASDAQ: SRPT) is Selling Shares

Yesterday, a Director at Sarepta Therapeutics (SRPT – Research Report), Richard Barry, sold shares of SRPT for $4.24M. Following Richard Barry’s last SRPT Sell transaction on September 16, 2019, the stock climbed by 54.2%. This is Barry’s first Sell trade

Mizuho Securities Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $183.00. The company’s shares closed last Friday at $139.34. According to TipRanks.com, Yang has currently 0 stars

H.C. Wainwright Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $260.00. The company’s shares closed last Thursday at $127.05. According to TipRanks.com, Chattopadhyay is a 5-star analyst

Sarepta Therapeutics (SRPT) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Martin Auster maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price target of $185.00. The company’s shares closed last Thursday at $126.25. According to TipRanks.com, Auster is a 5-star analyst

Sarepta Therapeutics (SRPT) Receives a Hold from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today. The company’s shares closed last Wednesday at $122.57. According to TipRanks.com, Singh is a 5-star analyst with an average return of 8.6% and a

RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $182.00. The company’s shares closed last Wednesday at $121.22. According to TipRanks.com, Abrahams is